Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Efficacy and safety of ciprofol versus propofol for the induction of anesthesia in adult patients: a multicenter phase 2a clinical trial

作者:Qianmei Zhu, Zhen Luo, Xia Wang, Dong‐Xin Wang, Dong‐Xin Wang, Jun Li, Xinchuan Wei, Jun Tang, Shanglong Yao, Wen Ouyang, Wensheng Zhang, Yunxia Zuo, Xiao Wang, Xiao Wang, Jin Liu · 发表于:International Journal of Clinical Pharmacy · 年份:2023 · DOI:10.1007/s11096-022-01529-x · 被引用次数:81 · 研究领域:Anesthesia and Sedative Agents、Cardiac, Anesthesia and Surgical Outcomes、Intraoperative Neuromonitoring and Anesthetic Effects

BACKGROUND: Ciprofol is a novel 2, 6-disubstituted phenolic derivative anesthetic that binds to the gamma-aminobutyric acid-A receptor. AIM: To determine the equally potent dose of ciprofol compared with propofol as an induction agent for general anesthesia in patients undergoing selective surgery, and to assess its safety. METHOD: A total of 109 patients undergoing selective non-emergency, non-cardiothoracic or non-neurosurgical surgery requiring tracheal intubation for general anesthesia were enrolled. Ten patients per group were assigned to ciprofol-0.3, 0.4 and 0.5 mg/kg, and propofol-2.0 or 2.5 mg/kg groups, respectively to receive an intravenous bolus dose. An additional 20 patients were enrolled in the ciprofol-0.3, 0.5 or propofol-2.0 mg/kg groups. The primary outcome was the success rate of induction defined as a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) ≤ 1 after the initial bolus dose. The secondary outcomes included the time to reach MOAA/S ≤ 1, the time to loss of the eyelash reflex, the incidences and severity of adverse events (AEs). RESULTS: The success rates were 100% for all 5 groups. The mean time to MOAA/S ≤ 1 and the time to loss of the eyelash reflex were not different among the 5 groups, regardless of whether a top-up dose was needed. There were no significant differences in the incidences and severity of AEs in the dose ranges investigated of ciprofol vs. propofol. CONCLUSION: The efficacy and safety of a single bolus dose of ciprof...